COBAS HPV TEST
Roche Molecular Systems, Inc. · Decision date Dec 15, 2025
What did the FDA decide?
FDA records P100020/S063 as a supplement to PMA P100020, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 15, 2025.
FDA approval order statement
different in-process testing for manufacturing kit reagents
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Dec 15, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P100020/S063
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- Decision code
- OK30
- Decision date
- Dec 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100020 · Original PMA
COBAS HPV TEST
P100020/S063 received
Application receipt date recorded by FDA.
P100020/S063 · FDA decision
30-Day Notice
P100020/S064 · Related supplement
cobas HPV
P100020/S065 · Related supplement
cobas HPV
P100020/S066 · Related supplement
cobas HPV
Timeline entries are records held by MedtechLedger for P100020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COBAS HPV TESTP100020 | Roche Molecular Systems, Inc. | PMA approval | Apr 19, 2011 | FDA |
cobas HPVP100020/S064 | Roche Molecular Systems, Inc. | PMA supplement | Dec 31, 2025 | FDA |
cobas HPVP100020/S065 | Roche Molecular Systems, Inc. | PMA supplement | Mar 17, 2026 | FDA |
cobas HPVP100020/S066 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP190028/S026 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Alinity m HR HPVP230003/S019 | Abbott Molecular, Inc. | PMA supplement | Sep 2, 2026 | FDA |
| Becton Dickinson and Company | PMA supplement | Aug 19, 2026 | FDA | |
BD Onclarity HPV AssayP160037/S028 | Becton Dickinson and Company | PMA supplement | Aug 14, 2026 | FDA |
Alinity m HR HPVP230003/S015 | Abbott Molecular, Inc. | PMA supplement | Jul 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P100020/S063
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





